Sign in
4

Changes in Ownership

CytomX Therapeutics, Inc. Filed Acc 0001140361-18-016993

Chief Financial Officer sold 3,000 shares at $28.12 ($84,360)

  • Chief Financial Officer acquired 3,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

RAY DEBANJAN · Chief Financial Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2018-04-02 Exercise or conversion : show line 1 in the form +3,000 $1.26 $3,780 7,741 D
2018-04-02 Sale : show line 2 in the form −3,000 $28.12 $84,360 4,741 D
Open-market sales · 3,000 sh · avg $28.12 · $84,360

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2018-04-02 Exercise or conversion : show line 3 in the form Stock Option (Right to Buy) −3,000 11,710 D
Loading xslF345X03/doc1.xml…